Home
- Belegger.nl: steun en toeverlaat voor beleggers. Bekijk de beurskoersen, de laatste stand van de AEX en lees het nieuws, de columns en de adviezen.
Koersen
- Aandelen
- Indices
- Valutas
- Rentes
- Commodities
- Certificaten
- Opties
- Futures
- Beleggingsfondsen
- Trackers
- Obligaties
- Hefboomproducten
Nieuws
Forum
Analyse & advies
Thema's
- Beurstips en handelskansen
- Fondsen & ETF's

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX: Euronext Amsterdam
BRU: Euronext Brussels
PSE: Euronext Paris
LIS: Euronext Lissabon
CHX: CBOE Europe, grote(re) EU aandelen
NAV: Investment Funds (NAV)

Noord-Amerika

NYS: New York Stock Exchange
OTC: CBOE BZX Exchange (US)
TSE: Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

Market Monitor

Crucell « Terug naar discussie overzicht

Zomaar ff tussendoor

44 Posts, Pagina: « 1 2 3 | Laatste

Omlaag ↓

flosz 18 augustus 2009 16:21

Project Number: 272200800056C-0-0-1
Title: ADVANCED DEVELOPMENT OF MULTIVALENT FILOVIRUS VACCINES
Organization: CRUCELL HOLLAND, BV

Year 2008
Funding IC NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
FY Total Cost by IC $13,496,364

This contract supports advanced development of a of multivalent filovirus (Ebola and Marburg) vaccine through cGMP manufacturing with an option for a Phase 1 clinical trial. Additional options provide for large scale production, development of a lyophilized formulation and a Phase 2 clinical trial.
projectreporter.nih.gov/project_info_...

[verwijderd] 26 mei 2010 22:08

Hier zou Flosz hem volgens mij zetten.
Thursday, May 20, 2010

Experimental Vaccine Protects Monkeys from New Ebola Virus

New research has found that an experimental Ebola vaccine developed by researchers at the National Institutes of Health protects monkeys against not only the two most lethal Ebola virus species for which it was originally designed, both recognized in 1976, but also against a newer Ebola virus species that was identified in 2007.

Nancy J. Sullivan, Ph.D., of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID), NIH, led the study team, which included collaborators from the U.S. Army Medical
Transmission electron micrograph of Ebola virus
View larger image
Credit: CDC
Research Institute of Infectious Diseases in Fort Detrick, Md, and the Centers for Disease Control and Prevention in Atlanta. Their findings appear May 20 in the open-access journal PLoS Pathogens. Currently, there are no specific treatments or vaccines available to control Ebola outbreaks.

“The important work by Dr. Sullivan and her colleagues shows that it is possible to generate immunity to newly identified species of Ebola virus with a vaccine originally designed to protect against a different species,” says NIAID Director Anthony S. Fauci, M.D. “This finding will guide future vaccine design and may open an avenue for developing a single vaccine that works against both known and emerging Ebola virus species.”

The experimental Ebola vaccine being developed at NIAID has two components, a prime and a boost. The prime consists of a DNA vaccine containing a small piece of genetic material encoding surface proteins from Zaire ebolavirus and Sudan ebolavirus. The boost consists of a weakened cold virus that delivers the Zaire ebolavirus surface protein.

Previously, Dr. Sullivan and her collaborators demonstrated that the prime-boost strategy produces a strong antibody response in monkeys. More importantly, the experimental vaccine induces a robust reaction by the cellular arm of the immune system. The cellular arm includes T cells, which help orchestrate the overall immune response.

“An ideal Ebola vaccine would stimulate broad immunity so that we wouldn’t have to scramble to create entirely new vaccines whenever new virus species are identified,” notes Dr. Sullivan.

However, developing one vaccine to protect against multiple Ebola virus species poses a challenge, she says. To the antibody-producing arm of the immune system, each species looks different. Neutralizing antibodies that recognize one Ebola species cannot readily recognize, or cross-neutralize, the others. T cells, in contrast, can cross-react, even when the target viruses share only small pieces in common.

After the emergence of Bundibugyo ebolavirus (BEBOV) in 2007, Dr. Sullivan’s team decided to revisit the prime-boost vaccine regimen to see if the cellular immunity generated would confer protection against the new virus species.

Four cynomolgus macaques received the DNA prime vaccine. A year later, the animals were boosted with the vector vaccine. Shortly after the boost, the four vaccinated monkeys and four unvaccinated ones
Researcher working in a biosafety level 4 laboratory
View larger image
Credit: U.S. Army Medical Research Institute of Infectious Diseases
serving as controls were exposed to lethal levels of BEBOV. All the unvaccinated animals became ill, and three died. None of the vaccinated animals showed any sign of illness. Analysis showed that the vaccinated monkeys developed T-cell responses sufficient to prevent or control infection by the novel Ebola virus species, even though the vaccine did not contain material from BEBOV and no antibodies against BEBOV were produced. The animal study was conducted in maximum-level biosafety containment laboratories at U.S. Army Medical Research Institute of Infectious Diseases.

Now the research team is evaluating what parts of the T-cell response were critical to the vaccine’s success against BEBOV. “Once we identify those critical aspects, we can design future vaccines to better elicit that desired immune cell-based activity and perhaps make a single vaccine that protects against all Ebola virus species,” says Dr. Sullivan.

For more information on NIAID research on Ebola and other hemorrhagic fever viruses, visit NIAID's Ebola/Marburg portal. ###
www.niaid.nih.gov/news/newsreleases/2...

MeawandMoo1 26 mei 2010 22:19

quote:
gocrucellgo schreef:
Hier zou Flosz hem volgens mij zetten.
Thursday, May 20, 2010

Experimental Vaccine Protects Monkeys from New Ebola Virus

tnx gocrucellgo en ab.

Ik ben zo vrij om de onderstaande ook te plaatsen:

www.fbo.gov/index?s=opportunity&m...

Solicitation Number:
M5Q50A032 Notice Type:

Award Notice Contract Award Date:
November 15, 2009

Contract Award Number:
V797P-5138B

Contract Award Dollar Amount:
1,282,040.00

Contractor Awardee:
CRUCELL VACCINES INC.;4216 PONCE DE LEON BLVD;CORAL GABLES;FL;331461827

Synopsis:
Added: Nov 10, 2009 12:02 pm
No Description Provided Point of Contact(s):
Deborah BukowskiContracting Officer
(708) 786-5219

maxen 26 mei 2010 23:11

quote:
gocrucellgo schreef:
Hier zou Flosz hem volgens mij zetten.
Thursday, May 20, 2010

Experimental Vaccine Protects Monkeys from New Ebola Virus

New research has found that an experimental Ebola vaccine developed by researchers at the National Institutes of Health protects monkeys against not only the two most lethal Ebola virus species for which it was originally designed, both recognized in 1976, but also against a newer Ebola virus species that was identified in 2007.

Nancy J. Sullivan,
...
The experimental Ebola vaccine being developed at NIAID has two components, a prime and a boost. The prime consists of a DNA vaccine containing a small piece of genetic material encoding surface proteins from Zaire ebolavirus and Sudan ebolavirus. The boost consists of a weakened cold virus that delivers the Zaire ebolavirus surface protein.

Previously, Dr. Sullivan and her collaborators demonstrated that the prime-boost strategy produces a strong antibody response in monkeys. More importantly, the experimental vaccine induces a robust reaction by the cellular arm of the immune system. The cellular arm includes T cells, which help orchestrate the overall immune response.
...

IMO een hernieuwde test met 'n prime-boost vaccin met een DNA vaccine van Vical als prime, en een Adenovirus-vector van Crucell als boost.
Deze combinatie blijkt nu ook tegen nieuwe Ebola/Marburg stammen effectief. Dat is mooi.

Onduidelijk blijft hier of ze voor de boost de oorspronkelijke Ad5, of een nieuwe Ad-vector (Ad35, Ad26?) gebruikt hebben, die Crucell voor het nieuwe ontwikkelprogramma uit 3 october 2008 gebruikt.

Onduidelijk is ook of er nog serieus naar een prime-boost vaccin voor ebola wordt toegewerkt (net als nu het geval lijkt te zijn met Crucell/GSK bij Malaria), of dat Crucell (met Ad-vectoren) of IBT (met z'n vlp's) het allein gaan worden. Is dit onderzoek een wetenschappelijk leukigheidje of een serieuze opmaat naar een prime-boost strategie? Ik vermoed dat zowiezo eerst maar eens een nieuwe phase I voor de nieuwe Crucell Ad-vector wordt afgewacht voordat uberhaupt aan een prime-boost phase I trial wordt begonnen. Zal zo'n vaartje niet lopen...

44 Posts, Pagina: « 1 2 3 | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX	911,23	-0,68	-0,07%	15:21
AMX	947,38	+8,53	+0,91%	15:21
ASCX	1.215,07	+10,00	+0,83%	15:06
BEL 20	3.968,67	-11,91	-0,30%	15:21
Germany40^	18.709,00	-33,22	-0,18%	15:20
US30^	39.481,80	+34,40	+0,09%	15:20
US500^	5.225,13	+1,71	+0,03%	15:20
Nasd100^	18.194,70	-10,10	-0,06%	15:21
Japan225^	38.399,00	+207,50	+0,54%	15:20
WTI	77,38	-1,82	-2,30%	15:20
Brent	82,16	-1,25	-1,50%	15:21
EUR/USD	1,0820	+0,0030	+0,28%	15:21
BTC/USD	61.804,98	-1.036,72	-1,65%	15:21
Gold spot	2.349,92	+13,16	+0,56%	15:21